<DOC>
	<DOCNO>NCT01193478</DOCNO>
	<brief_summary>The primary purpose study evaluate safety , tolerability , pharmacokinetics activity escalating , multiple , oral dos GS-5885 subject chronic genotype 1 Hepatitis C Virus ( HCV ) infection . Each participant study sequester clinic initial 5 day study .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study GS 5885 Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Chronically infect HCV genotype 1 HCV treatmentna√Øve Not coinfected HIV HBV HCV RNA viral load least 100,000 IU/mL BMI 19 35 kg/m2 Subject agree use highly effective contraception method female childbearing potential sexually active male . History clinicallysignificant illness major medical disorder may interfere subject treatment , assessment compliance protocol Decompensated liver disease cirrhosis evidence hepatocellular carcinoma Serological evidence coinfection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , another HCV genotype Subjects know , current use amphetamine and/or cocaine ; subject take methadone buprenorphine ( opioid replacement therapy ) ongoing alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>multiple ascend dose</keyword>
	<keyword>NS5A</keyword>
	<keyword>GS-5885</keyword>
	<keyword>chronic genotype 1 HCV infection</keyword>
</DOC>